Lataa...
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Fabry disease (FD) is a progressive multisystemic disorder, treatable with recombinant enzyme replacement therapy (agalsidase). However, recent studies suggest an endogenous inhibition of agalsidase in patients with FD, as reported for other lysosomal storage diseases. To assess the clinical consequ...
Tallennettuna:
| Julkaisussa: | J Am Soc Nephrol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Nephrology
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4696578/ https://ncbi.nlm.nih.gov/pubmed/25933799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014121226 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|